Drug intelligence / Profile preview

selected CD133+ cells

Development stage: Phase 2
Lead developer: Hospital Clínico San Carlos
Modality: Stem Cell Therapies → Cell Therapies
Administration: Parenteral

Overview

Selected CD133+ cells refer to an investigational autologous cell therapy consisting of endothelial progenitor cells (EPCs) isolated from a patient's peripheral blood. Developed by researchers at Hospital San Carlos in Madrid, the therapy involves mobilizing progenitor cells using granulocyte colony-stimulating factor (G-CSF), collecting them via apheresis, and selecting the CD133+ population using the CliniMACS system. The cells are then delivered via transendocardial injection into ischemic myocardial tissue, guided by electromechanical mapping (NOGA XP). The primary mechanism of action is therapeutic angiogenesis, where the progenitor cells promote the formation of new blood vessels to improve perfusion in patients with refractory angina who are not candidates for standard revascularization.

Other names: autologous CD133+ endothelial progenitor cellsautologous CD133+ cellsCD133+ EPCs

Beyond the preview

Go deeper on selected CD133+ cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on selected CD133+ cells.

Explore the full profile